I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Express Mail Label Number EV 590690225 US with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on

December 30, 2005
Date of Deposit

Mark G. Sandbaken, Reg. No. 39,354
Name of Applicant, Assignee or Registered Representative

Signature

December 30, 2005
Date of Signature



PATENT
Attorney Docket No.: 9632-006-999
Client Reference No.: CD30

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | |
|---|---|
| In re application of: | Confirmation No.: 7578 |
| Francisco et al. | Examiner: Misook Yu |
| Application No.: 09/724,406 | Art Unit: 1642 |
| Filed: November 28, 2000 | SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98 |
| For: RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references [excluding cited U.S. Patents, U.S. Patent Application publications, and appropriate IFW-stored, pending U.S. Patent Applications and portions thereof, per 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

The Commissioner is authorized to deduct the fee for this information disclosure statement from Deposit Account No. 502900. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Mark G. Sandbaken

Mark G. Sandbaken, Ph.D.
Reg. No. 39,354

SEATTLE GENETICS, INC.
21823 – 30th Drive SE
Bothell, WA 98021
Tel: 425-527-4138
Fax: 425-527-4001

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 2

| *Complete if Known* | |
|---|---|
| Application Number | 09/724,406 |
| Filing Date | 11/28/2000 |
| First Named Inventor | Francisco et al. |
| Art Unit | 1642 |
| Examiner Name | Misook Yu |
| Attorney Docket Number | 9632-006-999 |



## U.S. PATENT DOCUMENTS+

| Examiner Initials* | Cite No.[1] | Document Number: Number Kind Code[2] (*if known*) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|
| | | US 2004-0018194 A1 | 01-29-2004 | Francisco et al. | |
| | | US 2005-0123536 A1 | 06-09-2005 | Law et al. | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document: Country Code[3] | Number[4] | Kind Code[5] (*if known*) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | | WO | 97/17374 | | 05-15-1997 | Medac Gesellschaft ... | Pages 18-23 | ☐ |
| | | WO | 05/001038 | A2 | 01-06-2005 | Seattle Genetics | | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

| Substitute for form 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(use as many sheets as necessary)*<br>Sheet 2 of 2 | *Complete if Known* | |
|---|---|---|
| | *Application Number* | 10/983,340 |
| | *Filing Date* | November 5, 2004 |
| | *First Named Inventor* | Doronina, Svetlana O. |
| | *Art Unit* | 1614 |
| | *Examiner Name* | Unassigned |
| | *Attorney Docket Number* | 018891-001020US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|---|---|---|
| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
| | | Blast 2 Sequences Results (2 pages) | |
| | | BARTLETT et al., "Phase I Study of SGN-30, a Chimeric Monoclonal Antibody (mAb), in Patients with Refractory or Recurrent CD30 + Hematologic Malignancies," BLOOD Vol. 100(11), December, 2002, Abs 1403. | |
| | | Safety, Antitumor Activity and Pharmacokinetics of Six Weekly Doses of SGN-30 (anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies," BLOOD 102(11), 2003, Abs 2390. | |
| | | CERVENY et al., "Hodgkin's disease growth inhibition and sensitization to standard chemotherapeutics by the anti-CD30 monoclonal antibody SGN-30," PROC AM ASSOC CANCER RES vol. 45, March 2004, Abs 2258. | |
| | | CERVENY et al., "Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics," LEUKEMIA 19:1648-1655 (2005). | |
| | | CERVENY et al., "The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics," BLOOD 104(11), 2004, Abs 2639 | |
| | | KABAT et al., Sequences of Proteins of Immunological Interest, 5th Ed., NIH Publication No. 91-3242, pp. xv-xvi. | |
| | | KOON et al., "Anti-CD30 antibody based therapy," CURRENT OPINION IN ONCOLOGY 12:588-593 (2000) | |
| | | LEONARD et al., "Targeting CD30 as Therapy for Hodgkin's Disease. Phase II Results with the Monoclonal Antibody SGN-30," PROC AM SOC CLIN ONCOL April 2005, Abs 2553 | |
| | | LEONARD et al., "Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease," BLOOD 104(11) 2004, Abs 2635. | |
| | | WAHL et al., "The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease," CANCER RES. 62:3736-3742 (2002). | |
| | | | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.